| Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
|---|
| Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
|---|
| Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
|---|
Consistent with the Company’s guidance previously provided on September 4, 2024, the senior management team plans to:
•reiterate the shift of 20 to 30 cents of adjusted diluted EPS from Q3 to Q4. Therefore, the Company projects Q3 adjusted diluted EPS of between $1.31 to $1.41, with the remainder of the 2024 full year adjusted diluted EPS to be realized in Q4; and
•reiterate that, with regard to Medicare Advantage, the Company continues to be encouraged by the progress it has made in the improvement of its stars program performance.
Posted In: CNC
